https://scholars.lib.ntu.edu.tw/handle/123456789/593456
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Liao C.-M. | en_US |
dc.contributor.author | Shen H.-H. | en_US |
dc.contributor.author | CHI-LING CHEN | en_US |
dc.contributor.author | Hsu L.-I. | en_US |
dc.contributor.author | Lin T.-L. | en_US |
dc.contributor.author | Chen S.-C. | en_US |
dc.contributor.author | Chen C.-J. | en_US |
dc.date.accessioned | 2022-01-25T05:10:37Z | - |
dc.date.available | 2022-01-25T05:10:37Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0304-3894 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-64749101562&doi=10.1016%2fj.jhazmat.2008.10.095&partnerID=40&md5=33f3670cc10e31a6fed3dd815300b994 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/593456 | - |
dc.description.abstract | Previous epidemiological studies have indicated that ingested inorganic arsenic is strongly associated with a wide spectrum of internal cancers. Little is conducted, however, to assess health effects at long-term low dose exposures by linking biologically based mechanistic models and arsenic epidemiological data. We present an integrated approach by linking the Weibull dose-response function and a physiologically based pharmacokinetic (PBPK) model to estimate reference arsenic guideline. The proposed epidemiological data are based on an 8 years follow-up study of 10,138 residents in arseniasis-endemic areas in southwestern and northeastern Taiwan. The 0.01% and 1% excess lifetime cancer risk based point-of-departure analysis were adopted to quantify the internal cancer risks from arsenic in drinking water. Positive relationships between arsenic exposures and cumulative incidence ratios of bladder, lung, and urinary-related cancers were found using Weibull dose-response model r2 = 0.58-0.89). The result shows that the reference arsenic guideline is recommended to be 3.4 μg L-1 based on male bladder cancer with an excess risk of 10-4 for a 75-year lifetime exposure. The likelihood of reference arsenic guideline and excess lifetime cancer risk estimates range from 1.9-10.2 μg L-1 and 2.84 × 10-5 to 1.96 × 10-4, respectively, based on the drinking water uptake rates of 1.08-6.52 L d-1. This study implicates that the Weibull model-based arsenic epidemiological and the PBPK framework can provide a scientific basis to quantify internal cancer risks from arsenic in drinking water and to further recommend the reference drinking water arsenic guideline. ? 2008 Elsevier B.V. All rights reserved. | - |
dc.relation.ispartof | Journal of Hazardous Materials | - |
dc.subject | Arsenic; Cancer; Dose-response model; Drinking water; Risk assessment | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | Arsenic exposures; Bladder cancers; Cancer; Cancer risks; Dose response; Dose-response model; Drinking water; Epidemiological studies; Follow-up studies; Health effects; Inorganic arsenics; Integrated approaches; Low-dose exposures; Mechanistic models; Northeastern taiwan; Weibull; Weibull models; Wide spectrums; Arsenic; Health risks; Nonmetals; Physiological models; Potable water; Risk analysis; Risk management; Risk perception; Water analysis; Weibull distribution; Risk assessment; arsenic; drinking water; arsenic; cancer; dose-response relationship; drinking water; health impact; health risk; modeling; pollution effect; pollution exposure; risk assessment; adult; aged; article; bladder cancer; cancer incidence; cancer risk; controlled study; human; intestine cancer; kidney cancer; liver cancer; lung cancer; major clinical study; male; risk assessment; Taiwan; urinary tract cancer; Arsenic; Dose-Response Relationship, Drug; Environmental Exposure; Female; Humans; Male; Neoplasms; Pharmacokinetics; Risk Assessment; Taiwan; Water Pollutants, Chemical; Asia; Eurasia; Far East; Taiwan | - |
dc.title | Risk assessment of arsenic-induced internal cancer at long-term low dose exposure | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jhazmat.2008.10.095 | - |
dc.identifier.pmid | 19062162 | - |
dc.identifier.scopus | 2-s2.0-64749101562 | - |
dc.relation.pages | 652-663 | - |
dc.relation.journalvolume | 165 | - |
dc.relation.journalissue | 1-3 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。